4 results match your criteria: "University of Essen and the German Cancer Consortium[Affiliation]"
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
J Clin Oncol
December 2024
Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in overall survival (OS) and a numerically higher objective response rate (ORR) compared with nivolumab in the RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922). We report updated descriptive efficacy and safety results from RELATIVITY-047 with a median follow-up of 33.
View Article and Find Full Text PDFFirst-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
J Clin Oncol
November 2024
University of Essen and the German Cancer Consortium, Partner Site, Essen, Germany.
Article Synopsis
- Nivolumab combined with relatlimab and ipilimumab has been approved for treating advanced melanoma based on clinical trials, but no direct comparison of the two treatments existed, leading to an indirect comparison using patient-level data.
- The study utilized inverse probability of treatment weighting to balance patient characteristics and compared various outcomes like progression-free survival and treatment-related adverse events, finding both regimens had similar efficacy.
- Nivolumab plus relatlimab showed a better safety profile, with fewer severe side effects and treatment discontinuations than nivolumab plus ipilimumab, although some subgroup analyses suggested varying results.
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Clin Transl Sci
June 2024
Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Article Synopsis
- SAR439459 (SAR'459) is a new monoclonal antibody designed to improve the effects of immune checkpoint inhibitors, and it was tested for safety and effectiveness in patients with advanced solid tumors.* -
- The study, which consisted of multiple phases, revealed that the maximum dose tolerated was never reached, but adverse effects included significant events such as hemorrhagic issues and skin neoplasms.* -
- Ultimately, the combination therapy showed limited preliminary antitumor activity, which led to the decision to discontinue the study due to unclear effectiveness.*
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
J Clin Oncol
January 2023
Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
Article Synopsis
- A phase III trial, CheckMate 915, compared the effectiveness of combining nivolumab and ipilimumab with using nivolumab alone for treating high-risk resected melanoma patients.
- The study involved 1,833 participants, who were randomly assigned to either the combination therapy or nivolumab alone, focusing on recurrence-free survival (RFS) as the primary outcome.
- Results showed no significant difference in RFS between the two groups, with similar 24-month RFS rates; however, the combination therapy had higher rates of severe adverse events, reaffirming nivolumab as a standard treatment for melanoma adjuvant therapy.